Skip to main content
Toggle Menu
Home
ABOUT PhRMA
LEADERSHIP
BIOPHARMACEUTICAL SECTOR
MEMBER COMPANIES
CAREERS
CONTACT US
PRESS ROOM
PUBLICATIONS
ACCESS
INTERNATIONAL
DISASTER RELIEF
HEALTH CARE COMMUNICATIONS
PPA
PUBLIC PROGRAMS
MEDICARE PART D
INNOVATION
INTELLECTUAL PROPERTY
CLINICAL TRIALS
RESEARCH IN YOUR BACKYARD
INNOVATION HUB
MEDICINES IN THE PIPELINE
MEDICINES IN DEVELOPMENT
I AM RESEARCH. PROGRESS. HOPE.
STEM
VALUE
MEDICAL PROGRESS
BETTER HEALTH CARE
ADHERENCE TO MEDICATION
HEALTH CARE COSTS
ECONOMIC IMPACT
WE WORK FOR HEALTH
SAFETY
FOOD AND DRUG ADMINISTRATION
Prescription Drug User Fee Act (PDUFA)
COUNTERFEIT DRUGS
SUPPLY CHAIN SECURITY
IMPORTATION
PRESCRIPTION DRUG ABUSE
SAFE USE/DISPOSAL
DRUG SHORTAGES
PhRMApedia
PRESS ROOM
MEDIA CONTACTS
REPORTER'S HANDBOOK
COMPANY PRODUCTS BY CATEGORY
PRINCIPLES & GUIDELINES
Code on Interactions with Health Care Professionals
Clinical Trials
DTC Advertising
Office of Accountability
PUBLICATIONS
PROFILES & REPORTS
FACT SHEETS/POLICY PAPERS
NEWSLETTERS
SPEECHES & PUBLIC COMMUNICATION
TESTIMONY & PUBLIC COMMENTS
EVENTS
RESEARCH & HOPE AWARDS
ANNUAL MEETING ARCHIVE
THE CATALYST
ARCHIVE
CONTRIBUTORS
facebook
twitter
google plus
youtube
flickr
PhRMA
main
ABOUT PhRMA
LEADERSHIP
BIOPHARMACEUTICAL SECTOR
MEMBER COMPANIES
CAREERS
CONTACT US
PRESS ROOM
PUBLICATIONS
ACCESS
INTERNATIONAL
DISASTER RELIEF
HEALTH CARE COMMUNICATIONS
PPA
PUBLIC PROGRAMS
INNOVATION
INTELLECTUAL PROPERTY
CLINICAL TRIALS
INNOVATION HUB
MEDICINES IN THE PIPELINE
I AM RESEARCH. PROGRESS. HOPE.
STEM
VALUE
MEDICAL PROGRESS
BETTER HEALTH CARE
ECONOMIC IMPACT
SAFETY
FOOD AND DRUG ADMINISTRATION
COUNTERFEIT DRUGS
PRESCRIPTION DRUG ABUSE
SAFE USE/DISPOSAL
DRUG SHORTAGES
PhRMApedia
PRESS ROOM
PRINCIPLES & GUIDELINES
PUBLICATIONS
EVENTS
THE CATALYST
ARCHIVE
CONTRIBUTORS
PhRMA Comments on Alternative Approval Pathway
04.18.13 |
By
phrma_admin
PhRMA Comments on Alternative Approval Pathway
phrmacommentsonalternativeapprovalpathwayfda-2012-n-1248final.pdf
Sign-up for Updates
Share
Email
Print
